Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CD19-BCMA CAR-T cell therapy / Shanghai Ultra-T Immune Therap
ChiCTR2100041955: A safety and efficacy preliminary clinical study of KQ-19B CAR-T cells for the treatment of relapse/refractory multiple myeloma	Recruiting	N/A	19		1.0*10^6 CAR+T cells/kg ;2.5*10^6 CAR+T cells/kg ;5.0*10^6 CAR+T cells/kg ;（1.0-5.0）*10^6 CAR+T cells/kg	Shanghai Changzheng Hospital Onset; Shanghai Changzheng Hospital, Shanghai Ultra-T Immune Therapeutics Co. LTD	Multiple myeloma